Group 1 - The core viewpoint of the news is the performance and holdings of the Fuqua Precision Medical Mixed A Fund, which has shown significant growth in recent months and year-to-date [1] - As of June 4, 2025, the latest net value of the fund is 3.1336 yuan, reflecting a growth of 1.37% [1] - The fund's one-month return is 9.95%, ranking 66 out of 2330 in its category, while its three-month return is 30.39%, ranking 10 out of 2320 [1] - Year-to-date, the fund has achieved a return of 40.63%, ranking 12 out of 2307 [1] Group 2 - The top ten stock holdings of the Fuqua Precision Medical Mixed A Fund account for a total of 69.71%, with significant positions in companies such as Baile Tianheng (9.66%), Haizike (9.65%), and Kelun Pharmaceutical (9.10%) [1] - The fund was established on November 16, 2017, and as of March 31, 2025, it has a total scale of 3.746 billion yuan [1] - The fund manager, Zhao Wei, has extensive experience in the pharmaceutical and investment sectors, having held various positions in companies such as GlaxoSmithKline and China Merchants Fund Management [2]
6月4日富国精准医疗混合A净值增长1.37%，今年来累计上涨40.63%
Sou Hu Cai Jing·2025-06-04 16:00